Abstract. Multidrug resistance (MDR) is a major obstacle to cancer chemotherapy efficacy. In the present study, 6-O-angeloylplenolin repressed the overexpression of ATP binding cassette subfamily B member 1 (MDR1) and increasing the intracellular concentration of anticancer drugs. A reduction in P-glycoprotein expression (encoded by MDR1) was observed in parallel with a decline in mRNA expression in vincristine-resistant HCT (HCT-8/VCR) cells treated with 6-O-angeloylplenolin. In addition, 6-O-angeloylplenolin suppressed the activity of the MDR1 gene promoter. Treatment with 6-O-angeloylplenolin also decreased the amount of the specific protein complex that interacted with the MDR1 gene promoter in HCT-8/VCR cells, potentially leading to the suppression of MDR1 expression. Treatment with 6-O-angeloylplenolin inhibited the nuclear translocation of Y-box binding protein-1 in HCT-8/VCR cells treated with 6-O-angeloylplenolin, contributing to the negative regulation of MDR1. Finally, 6-O-angeloylplenolin reversed VCR resistance in an HCT/VCR xenograft model. In conclusion, 6-O-angeloylplenolin exhibited a MDR-reversing effect by downregulating MDR1 expression and could represent a novel adjuvant agent for chemotherapy.
Introduction
Multidrug resistance (MDR) is a major obstacle to successful cancer chemotherapy. MDR is often associated with the overexpression of the ATP binding cassette subfamily B member 1 (ABCB1, also known as MDR1) gene, which encodes P-glycoprotein (P-gp) (1, 2) . P-gp expression enhances drug efflux pump activity, depleting the intracellular concentration of anticancer drugs, driving drug resistance. Various environmental stimuli, including an inverted CCAAT box, can activate the MDR1 promoter (3) (4) (5) , which directly interacts with Y-box-binding protein (YB-1) (5-9). Assays into MDR1 promoter activity using reporter genes demonstrated that the nuclear translocation of YB-1 was able to activate the MDR1 promoter (5,7), contributing to the expression of MDR1 and to drug resistance (5, 9) . In addition, the expression of MDR1 was also observed in tumor specimens derived from cancer patients (9) (10) (11) . Therefore, the nuclear localization of the YB-1 is a notable marker of disease progression (6) . Moreover, multidrug resistance-associated protein 1 (MRP1) is a protein encoded by the ABCC1 gene in human, which may interacted with MDR1 to regulate the drug resistant as well (12) . However, a previous study revealed that the amount of nuclear YB-1 was not associated with MDR1 expression (13) . The mechanism of YB-1 nuclear translocation is presently unclear, meaning that further research is required.
The sesquiterpene lactone 6-O-angeloylplenolin, a bioactive component of Centipeda minima (L.) A (14) , has been reported to have various biological activities, including antiprotozoal and antibacterial activities (15) . It was previously reported that 6-O-angeloylplenolin induced apoptosis through a mitochondrial/caspase pathway in acute promyelocytic leukemia HL-60 cells (16) ; it was also reported to trigger mitotic arrest and caspase-dependent apoptosis in human multiple myeloma cells (17) . The result of proteome microarray analysis revealed that 6-O-angeloylplenolin inhibited S-phase kinase-associated protein 1 (Skp1) and signal transducer and activator of transcription 3 to repress Skp2, exhibiting inhibitory effects on lung cancer cell proliferation (18) . In addition, it was reported that a number of sesquiterpene lactones could bind specifically to human P-gp and reverse cellular multidrug 
Materials and methods
Chemicals, cell lines and cell culture. 6-O-angeloylplenolin (also known as brevifolin or brevilin-A) (Fig. 1A) was isolated from C. minima in Capital Medical University (Beijing China), as described previously (17) . The purity of 6-O-angeloylplenolin was >97% (HPLC). The human colon carcinoma HCT-8 cell line and its MDR variant HCT-8/VCR were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Cells were maintained in RPMI 1640 (Life Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies; Thermo Fisher Scientific, Inc.), penicillin (100 ng/ml) and streptomycin (100 ng/ml) in a humidified atmosphere with 5% CO 2 at 37˚C. HCT-8/VCR cells were grown under the same conditions, but the medium contained 2 mg/l vincristine (Sigma Aldrich; Merck KGaA, Darmstadt, Germany), which was removed for 1 week prior to assay commencement. In terms of cell proliferation and cell cycle distribution, there was no significant difference between these two cell lines.
MTT assay. The MTT colorimetric assay was performed as described by Mosman et al (20) . HCT-8 or HCT-8/VCR cells were seeded into 96-well plates at a density of 1x10 4 cells/well. The cytotoxicity of 6-O-angeloylplenolin, vincristine, mitomycin (Sigma Aldrich; Merck KGaA), hydroxycamptothecin (Sigma Aldrich; Merck KGaA) or the compounds in combinations in HCT-8 and HCT-8/VCR cells was analyzed by MTT assay following incubation of cells with these compounds for 24 h. The concentrations of vincristine, mitomycin or hydroxycamptothecin were 1, 3, 10, 30, 100 and 300 µg/ml. The cytotoxicity was expressed as the half-maximal inhibitory concentration (IC 50 ), which was extrapolated from linear regression analysis of experimental data.
Detection of intracellular vincristine accumulation.
High-performance liquid chromatography (HPLC) was used to measure the accumulation of drugs in cells and tissue, as described previously (21) . HCT-8/VCR cells were incubated with 6-O-angeloylplenolin for 24 h and then the cells were treated with 80 µg/ml vincristine for 12 h. A total of 1x10 6 cells were collected and centrifuged at 4˚C for 10 min at 15,996 x g. The supernatant was discarded. The cell pellet was resuspended and lysed (Cell Signaling Technology, Inc. Danvers, MA, USA) for 10 min at 4˚C. A total of 50 µl cell lysate samples were taken for HPLC evaluation. The concentrations of vincristine were determined by HPLC as described by Chinese pharmacopoeia (22) . Briefly, separation was performed on a C 18 column (Eclipse C 18 , 150 by 4.6 mm, with a particle size of 5 µm; Agilent Technologies, Inc., Santa Clara, CA, USA) at 20˚C. The mobile phase was a 55:45 (v/v) mixture of methanol and 60 mM sodium phosphate buffer (pH 3.0). The UV detector was set at wavelength of 297 nm. Data were expressed as the ratio of the peak area to that of the internal standard.
Adriamycin and Rh123 accumulation assay. Accumulation of the fluorescent compounds adriamycin (Sigma-Aldrich; Merck KGaA) and Rh123 (0.5 mg/ml; Sigma-Aldrich; Merck KGaA) were used as a functional index of P-gp, as described previously (5, 23) . HCT-8/VCR cells (1x10 4 cells/well) were first treated with 0.35, 0.7 and 1.4 µM 6-O-angeloylplenolin for 24 h. Next, one group of cells were treated with 12 µM verapamil for 12 h, which was used as the positive control (24) . Following this, the cells were incubated in medium containing 50 µM adriamycin and 10 µM Rh123 for 3 h. Finally, the cells were washed twice with PBS prior to measurement. The fluorescence intensity of were detected by fluorospectrophotometer (Synergy 2, BioTek Instruments, Inc., Winooski, VT, USA) for Rh123 at 530 nm (excitation wavelength, 500 nm) and adriamycin at 530 nm (excitation wavelength, 485 nm).
Determination of gene expression by reverse transcriptionquantitative polymerase chain reaction (RT-qPCR).
HC T-8/ VC R c el l s we r e t r e a t e d w it h 1. 4 µM 6-O-angeloylplenolin for 12 h. (4); and GAPDH forward, 5'-GTCA ACG GAT TTG GTC GTA TT-3' and reverse, 5'-AGT CTT CTG GGT GGC AGT GAT-3'. The PCR products were separated by electrophoresis on an 1.5% agarose gel and stained with 0.1 µg/ml ethidium bromide. Differential gene expression was quantified using the Image Analysis system, version 3 (FR-980A gel Image Analysis System, Shanghai Furi Science and Technology Co., Ltd., Shanghai, China). Western blot analysis. Following treatment with 0.35, 0.7 or 1.4 µM 6-O-angeloylplenolin for 12 h, the cytosolic and nuclear proteins in HCT-8/VCR cells were extracted described previously (26) . A total of 20 µg total cytosolic and nuclear proteins were separated by 12% SDS-PAGE. Following electrophoresis, the proteins were transferred to a polyvinylidene difluoride (PVDF) membrane, which were blocked with 3% BSA at room temperature for 1 h. The PVDF membranes were incubated with anti-YB-1 (monoclonal rabbit IgG; Cell Signaling Technology, Inc.) or rabbit anti-GAPDH antibody (dilution, 1:5,000; Sigma-Aldrich, Merck KGaA; cat. no. PLA0125) antibodies at 4˚C for overnight. The primary antibodies were detected with anti-rabbit IgG conjugated to alkaline phosphatase (1:3,000 dilutions, Bio-Rad Laboratories, Inc., Hercules, CA, USA; cat. no. 170-6518) to generate a BCIP/NBT (Promega Corporation, Madison, WI, USA; cat. no. S3771) signal. Gel analysis was performed with Image Lab 3.0 software (Bio-Rad Laboratories, Inc.).
Transient transfection and luciferase assay.
Plasmid construction was performed as described previously (7, 27) . HCT-8/VCR cells were seeded into six-well plates (3x10 5 cells/well) and incubated for 24 h before transfection. Using Lipofect Transfection reagent (Beijing Tiangen Biotech Co., Ltd., Beijing, China), the cells were co-transfected with 4 µg/well plasmid pGL3-MDR1 (Promega Corporation, Madison, WI, USA). The sequence for MDR1 promoter was: Forward, 5'-CTA GAG AGG TGC AAC GGA-3' (-198 to -181) and reverse, 5'-GCG GCC TCT GCT TCT TTG A-3' (+25 to +43). Next, the cells were treated with 0.35, 0.7 or 1.4 µM 6-O-angeloylplenolin for 24 h. Firefly and Renilla luciferase activities in 1x10 4 cells/well were measured using the Dual-Luciferase Assay system (Promega Corporation) using a Microplate Luminometer (Berthold Technologies GmbH, Bad Wildbad, Germany). Electrophoretic mobility shift assay (EMSA). HCT-8/VCR (3x10 5 cells/well) cells were treated with 0.35, 0.7 or 1.4 µM 6-O-angeloylplenolin for 12 h and the EMSA was performed as described by Han et al (24) . The DNA sequence of the ds-oligomer used was a CAAT-like motif (5'-ATC AGC ATT CAG TCA ATC CGG GCC-3') (5,7). The gels were stained using the EMSA kit (Invitrogen; Thermo Fisher Scientific, Inc.) as described by the manufacturer and images were captured using an Olympus Standard fluorescence microscope (Olympus Corporation, Tokyo, Japan). The magnification used was x100. , the mice were randomly assigned to 5 groups and received the following treatments for 12 days: Control (PBS), 6-O-angeloylplenolin (7 mg/kg per day, oral), VCR (2.5 mg/kg per day, oral), VCR + 6-O-angeloylplenolin (3.5 mg/kg per day, oral), VCR + 6-O-angeloylplenolin (7 mg/kg per day, oral). Following 12 days, the tumors were isolated and weighed. The tumor growth inhibitory rate (IR) was calculated as follows: IR (%)=1-(TW treated /TW control )x100. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Capital Medical University.
Statistical analysis. Statistical analysis was performed using one-way analysis of variance followed by Dunnett's test (version 5.0; GraphPad Software, Inc., La Jolla, CA, USA). All results are presented as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.
Results

MDR-reversing effect of 6-O-angeloylplenolin. HCT-8 and
HCT-8/VCR cells were incubated with vincristine, mitomycin and hydroxycamptothecin for 24 h and subjected to MTT assays to assess cell viability. HCT-8/VCR cells were significantly more resistant to vincristine, 6-O-angeloylplenolin, mitomycin and hydroxycamptothecin than HCT-8 cells (Table Ι) . Treatment with 1.4 µM 6-O-angeloylplenolin had no significant effect on the viability of HCT-8/VCR cells. Therefore, the concentration of 6-O-angeloylplenolin was applied to indicate a reversal of resistance. HCT-8/VCR cells were co-incubated with 1.4 µM 6-O-angeloylplenolin and one of three anti-cancer drugs vincristine, mitomycin or hydroxycamptothecin for 24 h. The concentrations of vincristine, mitomycin or hydroxycamptothecin were 1, 3, 10, 30, 100 and 300 µg/ml. The results of the MTT assay revealed that 1.4 µM 6-O-angeloylplenolin significantly increased the cytotoxicity of each of the three anticancer drugs on HCT-8/VCR cells (Table Ι) .
Treatment with 6-O-angeloylplenolin increases the intracellular accumulation of vincristine, adriamycin and Rh123.
Inhibiting drug efflux and increasing the intracellular accumulation of drugs is an effective way of overcoming drug resistance (24) . To investigate whether 6-O-angeloylplenolin increased the intracellular accumulation of vincristine, adriamycin and Rh123 in HCT-8/VCR cells, HPLC and fluorescence intensity assays were performed. The results indicated that 6-O-angeloylplenolin significantly increased the intracellular accumulation of vincristine, adriamycin and Rh123 in HCT-8/VCR cells following treatment with 6-O-angeloylplenolin for 24 h ( Fig. 1B and C; P<0 .01).
Treatment with 6-O-angeloylplenolin does not alter the expression of MRP1 and YB-1.
It is reported that vincristine is susceptible to common mechanisms of multidrug resistance, including the overexpression of P-gp (28) . Here, 6-O-angeloylplenolin did not affect the expression of MRP1 in colon cancer cells. This result indicated that 6-O-angeloylplenolin reversed vincristine resistance by suppressing MDR1 expression. Moreover, 6-O-angeloylplenolin had no effect on the expression of YBX1, which encodes YB-1 ( Fig. 2A and B) . These results indicated that 6-O-angeloylplenolin suppressed YB-1 nuclear translocation, but not YB-1 expression. (Fig. 2) , Table Ι . Cytotoxicity of drugs in HCT-8 and HCT-8/VCR cells by MTT assay. in parallel with a reduction of the protein expression of MDR1 (Fig. 3A) .
Treatment with 6-O-angeloylplenolin downregulates expres-
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Treatment with 6-O-angeloylplenolin suppresses MDR1
promoter activity. To determine whether the CAAT segment of the MDR1 promoter was regulated by 6-O-angeloylplenolin or not, the wild-type MDR1 promoter (residues -198 to +43,241 bp) DNA fragment was cloned into a luciferase-expressing pGL3-basic vector to construct pGL3-MDR, as described previously (27) . The data revealed that there was an 18-fold increase in MDR1 promoter activity in HCT-8/VCR cells transiently transfected with dual-reporter gene vectors, compared with the level in HCT-8 (Fig. 3B) . MDR1 promoter activity was significantly decreased in HCT-8/VCR cells following incubation with 6-O-angeloylplenolin for 24 h (Fig. 3B) .
6-O-angeloylplenolin suppresses YB-1 nuclear translocation.
Whether the expression and localization of YB-1 is associated with the expression of MDR1 gene is key to understanding the mechanism of P-gp action. To confirm the effect of 6-O-angeloylplenolin on YB-1 nuclear translocation, western blot analysis was performed. Compared with HCT-8 cells, nuclear translocation of YB-1 was enhanced in HCT-8/VCR cells. The data revealed that 6-O-angeloylplenolin effectively inhibited the nuclear translocation of YB-1 in HCT-8/VCR cells (Fig. 4A-C) .
6-O-angeloylplenolin downregulates MDR1 expression by decreasing binding of MDR1 promoter with nuclear transcription factors.
A number of studies (29, 30) have provided evidence implicating complex mechanisms for the transcriptional regulation of MDR1 in human cancer cells. Since the present study demonstrated that 6-O-angeloylplenolin could inhibit the expression of MDR1 mRNA, it was necessary to examine whether 6-O-angeloylplenolin had any effect on MDR1 promoter. An EMSA was performed using a probe from the MDR1 promoter sequence, -86 to -67 bp. The amount of specific protein complex interacting with the probe was lower in the HCT-8 cells than in HCT-8/VCR cells ( Fig. 4D; lanes 2-3) . Treatment with 6-O-angeloylplenolin decreased the number of protein/DNA complexes in HCT-8/VCR cells (Fig. 4B,  lanes 3-6) . This result indicated that 6-O-angeloylplenolin inhibited the binding of nuclear proteins to the CAAT region of the MDR1 promoter in HCT-8/VCR cells, which could result in the inhibition of MDR1 expression. The data demonstrated that 6-O-angeloylplenolin or vincristine treatment alone had no effect on tumor growth. However, the combination of 6-O-angeloylplenolin with vincristine significantly inhibited tumor growth (Fig. 5A and B) . In addition, the body weights of mice were stable, indicating the combination treatments were tolerable (Fig. 5C ).
6-O-angeloylplenolin reverses VCR resistance in HCT/
Discussion
Resistance to chemotherapeutics remains a major cause of cancer treatment failure. Thus, in addition to investigating more efficient therapeutic drugs, there is a requirement to develop compounds to inhibit MDR activity or to synergize with existing treatments. The current study revealed that 6-O-angeloylplenolin treatment reversed vincristine resistance in HCT-8/VCR cells, increasing the intracellular accumulation. MDR is often associated with the overexpression of MDR1, which causes the enhancement of drug efflux pump activity and drug resistance (29) . Treatment with 6-O-angeloylplenolin inhibited the expression or function of P-gp, data that were further supported by RT-PCR, flow cytometry and promoter activity analysis.
Several approaches to overcoming MDR have been proposed (12, 28, 29) ; of them, inhibition of MDR-associated genes has promise. P-gp is encoded by MDR1, which was investigated in the present study. The expression of MDR1 was depleted following 6-O-angeloylplenolin administration. Besides P-gp, MRP1 is another protein that is important to MDR; it is encoded by MRP1. The results of the present study indicated that the mRNA level of MRP1 was unchanged following 6-O-angeloylplenolin treatment (Fig. 2) and that 6-O-angeloylplenolin exerts its main effect via regulating the expression of MDR1 in vitro.
Previous reports have demonstrated that YB-1 activity is closely associated with the expression of MDR1 in vivo and in vitro (5) (6) (7) (8) (9) . Treatment with 6-O-angeloylplenolin decreased the level of YB-1 in nucleus and complexes of this nuclear protein with MDR1 promoter in a dose-dependent manner. However, 6-O-angeloylplenolin regulating the expression of YBX1 on mRNA level was not observed. Therefore, 6-O-angeloylplenolin regulated the expression of MDR1 by inhibiting YB-1 nuclear translocation, not by depressing its expression. These findings differ from previous reports (9, 12) , which might be due to the different tumor type. Therefore, these novel results shed light on the mechanism of chemotherapy resistance in colon cancer. These results provide evidence for the combination use of 6-O-angeloylplenolin with vincristine in patients with refractory colon cancer. However, there were certain limitations to the current study. The detailed interaction between YB1 and MDR1 following 6-O-angeloylplenolin treatment in colon cancer was not clarified. Future studies should focus on the protein kinase B-nuclear factor-κB-YB-1-MDR1 and tumor protein p53-YB-1-MDR1 signaling pathways in the future.
Taken together, the results of the present study indicated that 6-O-angeloylplenolin displayed a significant antitumor activity by reserving drug resistance. The effect of 6-O-angeloylplenolin was exerted via inhibition of the intracellular accumulation of YB-1 and the expression of MDR1, resulting in a decrease in efflux pump activity. These results demonstrated that 6-O-angeloylplenolin may represent a potential anticancer drug adjuvant with the potential to reverse drug resistance.
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